NASDAQ
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026....
Frontier Capital Management Co. LLC lowered its stake in Tempus AI, Inc. (NASDAQ: TEM) by 10.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange C...
TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach....
Tempus AI's shift toward scalable revenues, high-margin data services and broader AI capabilities defines a pivotal moment for TEM investors....
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up....
Cathie Wood bought shares of Baidu, WeRide, and Tempus AI on Monday. Baidu has rallied on its rising AI chips business in China, but it's still textbook cheap....
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presen...
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner....
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark....
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition....
No price data available for this timeframe.